Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA Post published:September 20, 2023 Post category:Press Release
Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD Post published:September 12, 2023 Post category:Press Release
Silo Pharma Engages Clarivate for Intellectual Property and Patent Management Post published:August 10, 2023 Post category:Press Release
Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders Post published:August 8, 2023 Post category:Press Release
Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded U.S. Patent Post published:June 21, 2023 Post category:Press Release
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic Post published:June 13, 2023 Post category:Press Release
Silo Pharma Announces Participation on Webull Corporate Communications Service Platform Post published:June 2, 2023 Post category:Press Release
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21 Post published:May 30, 2023 Post category:Press Release
Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease Post published:May 9, 2023 Post category:Press Release
Silo Pharma to Present at Psychedelic Drug Development Conference Post published:April 24, 2023 Post category:Press Release